Francisco J. Esteva, MD, PhD

Francisco J. Esteva, MD, PhD, discusses the phase 3 monarchE and NATALEE trials in patients with hormone receptor–positive/HER2-negative breast cancer.

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States.

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, director, Breast Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the use of trastuzumab biosimilars in the treatment of patients with breast cancer.

Francisco J. Esteva, MD, PhD, director, Breast Medical Oncology, professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the prevalence of precision medicine in the treatment of patients with breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the efficacy and safety of the trastuzumab (Herceptin) biosimilar candidate CT-P6 in HER2-positive breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the impact of the approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses next-generation sequencing in metastatic breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, NYU Langone Medical Center, discusses the clinical implications of genomic testing in breast cancer.

Francisco J. Esteva, MD, PhD, medical oncologist, New York Langone Medical Center, discusses the importance of having a clinical trial of the trastuzumab (Herceptin) biosimilar MYL-1401O for patients with HER2-positive breast cancer.

Francisco J. Esteva, MD, PhD, medical oncology, New York Langone Medical Center, discusses a phase III study of the biosimilar version of trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.